Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Madison L. Esposito and Michelle Kahn-John, PhD, RN
Most clinicians receive little training in integrating Native healing into allopathic practice, which undermines patients’ autonomy and cultural values.
AMA J Ethics. 2020;22(10):E837-844. doi:
10.1001/amajethics.2020.837.
In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.
AMA J Ethics. 2018;20(11):E1082-1093. doi:
10.1001/amajethics.2018.1082.